JP2022500351A5 - - Google Patents
Info
- Publication number
- JP2022500351A5 JP2022500351A5 JP2020567621A JP2020567621A JP2022500351A5 JP 2022500351 A5 JP2022500351 A5 JP 2022500351A5 JP 2020567621 A JP2020567621 A JP 2020567621A JP 2020567621 A JP2020567621 A JP 2020567621A JP 2022500351 A5 JP2022500351 A5 JP 2022500351A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- hydroxypiperidine
- bipyridine
- methanone
- benzyl
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733927P | 2018-09-20 | 2018-09-20 | |
| US62/733,927 | 2018-09-20 | ||
| PCT/JP2019/038061 WO2020059894A1 (en) | 2018-09-20 | 2019-09-19 | CH24H Inhibitors For Pain Use |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500351A JP2022500351A (ja) | 2022-01-04 |
| JP2022500351A5 true JP2022500351A5 (https=) | 2022-09-20 |
| JPWO2020059894A5 JPWO2020059894A5 (https=) | 2022-09-20 |
| JP7443255B2 JP7443255B2 (ja) | 2024-03-05 |
Family
ID=68343384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567621A Active JP7443255B2 (ja) | 2018-09-20 | 2019-09-19 | 疼痛使用のためのｃｈ２４ｈ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210346366A1 (https=) |
| EP (1) | EP3852757A1 (https=) |
| JP (1) | JP7443255B2 (https=) |
| WO (1) | WO2020059894A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025126159A1 (en) * | 2023-12-15 | 2025-06-19 | Takeda Pharmaceutical Company Limited | A method for treating a neurological disease in a recreational drug user |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2763979T3 (pl) * | 2011-10-07 | 2019-06-28 | Takeda Pharmaceutical Company Limited | Związki 1-arylokarbonyl-4-oksy-piperydynowe użyteczne do leczenia chorób neurodegeneracyjnych |
| EP3904332B1 (en) | 2011-10-14 | 2024-12-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain |
| PE20151162A1 (es) | 2012-12-11 | 2015-08-28 | Takeda Pharmaceutical | Compuestos heterociclicos inhibidores del colesterol 24-hidroxilasa (ch24h) |
| CN105164161A (zh) * | 2013-03-13 | 2015-12-16 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| JP6272832B2 (ja) * | 2013-04-04 | 2018-01-31 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3152198B1 (en) | 2014-06-09 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
-
2019
- 2019-09-19 EP EP19794269.1A patent/EP3852757A1/en not_active Withdrawn
- 2019-09-19 WO PCT/JP2019/038061 patent/WO2020059894A1/en not_active Ceased
- 2019-09-19 US US17/277,917 patent/US20210346366A1/en not_active Abandoned
- 2019-09-19 JP JP2020567621A patent/JP7443255B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10633413B2 (en) | Methods of treating Parkinson's disease using aminosterols and compositions comprising the same | |
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| US12102637B2 (en) | Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis | |
| MX2010005680A (es) | Composiciones de tapentadol. | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| TW200942235A (en) | Dosing regimen for a selective S1P1 receptor agonist | |
| US20190054088A1 (en) | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis | |
| CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| JP5757544B2 (ja) | 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法 | |
| JP2015517523A5 (https=) | ||
| JP2025060685A (ja) | ピリダジノンｔｒｐｃ５阻害剤の噴霧乾燥された製剤 | |
| CA2688542C (en) | Methods and compositions for administration of oxybutynin | |
| JP2003519181A (ja) | 抗高血圧剤に対する抵抗性及び関連状態を処置する方法及び処方物 | |
| JP2019507786A5 (https=) | ||
| JP2022500351A5 (https=) | ||
| TW202339731A (zh) | 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法 | |
| US11833119B2 (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| JP2020512292A5 (https=) | ||
| CN114786647A (zh) | 口服药学立即释放组合物和用于重量减轻的治疗方法 | |
| JP2021530568A5 (https=) | ||
| JPWO2020059894A5 (https=) | ||
| TW200423929A (en) | Pharmaceutical combination | |
| JP2000513349A (ja) | パーキンソン病の治療における使用のためのロピニロールおよびｌ―ｄｏｐａの組み合わせ | |
| JP6878021B2 (ja) | トリプタンとアスコルビン酸を含有する医薬組成物 | |
| EA046645B1 (ru) | Фармацевтические препараты для лечения эндометриоза, миомы матки, синдрома поликистоза яичников или аденомиоза |